Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2004

View Archived Issues

Vasogen highlights FY 2003 developments

CuraGen continues to advance pipeline of protein, antibody and small molecule therapeutics

Low levels of free testosterone may increase risk of Alzheimer disease

Migraine sufferers with aura and at least one attack per month at risk for cerebral infarction

CE Mark for Matritech NMP22 products

Ivax's generic glyburide/metformin hydrochloride receives approval

Pfizer discontinues development of DK-507k

GeneMax acquires license to novel assay technology

Enrollment completed in phase IIa IPL-512602 study

OraDisc A NDA accepted for filing

Phenanthrene-based glucocorticoid receptor modulators newly developed at Pfizer

Alrex safe for long-term treatment of seasonal allergic conjunctivitis

Novel cholesterol absorption inhibitors discovered at AstraZeneca

Novartis presents new modulators of Smac/IAP interaction

New tubulysin conjugates for cancer therapy claimed by Morphochem

Phase I trial of PT-523 commences enrollment

New protein kinase inhibitors for cancer therapy designed at Novartis

Novartis presents novel tyrosine kinase inhibitors with utility in leukemia

New antitumor fredericamycin derivatives discovered at Biofrontera

New program for Protherics' Angiotensin Vaccine

Novel probucol derivatives with improved PK profile presented by AtheroGenics team

Surfaxin selected for CMA Pilot 2 Program

Clinical benefits induced by roflumilast in the treatment of asthma

Promising phase III results found for indiplon in chronic insomnia

Preliminary efficacy results of a Zadaxin triple therapy in hepatitis C

Poor efficacy reported for vaccines against HIV infection

Yamanouchi and Fujisawa announce agreement to merge in 2005

NPC1L1 identified as a protein involved in intestinal cholesterol absorption and action of ezetimibe

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.